BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation

BACKGROUND: Mutated epidermal growth factor receptor (EGFR) is one of the most successful targets in cancer targeted therapy. While this treatment has benefited many patients with an activating EGFR mutation (EGFRm), almost all those who initially benefited will eventually develop acquired drug resi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cell Biosci
Hauptverfasser: Zhan, Yihong, Wang, Yue, Qi, Miao, Liang, Panpan, Ma, Yu, Li, Ting, Li, Hui, Dai, Congmei, An, Zhifeng, Qi, Yitao, Wu, Hongmei, Shao, Huanjie
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2019
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6651933/
https://ncbi.nlm.nih.gov/pubmed/31367332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13578-019-0322-y
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge